Biodesix to Report Second Quarter 2021 Financial Results on August 10, 2021
Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung, including three proteomic tests.
- Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung, including three proteomic tests.
- The antibody tests can detect antibodies that are generated both from infection by the virus and from the vaccines.
- Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors.
- Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law.